We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+8.36%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
+$184M
Cap. Flow
+$269M
Cap. Flow %
24.82%
Top 10 Hldgs %
42.57%
Holding
126
New
25
Increased
29
Reduced
26
Closed
35

Top Buys

Rank Stock Value
1
TMCI icon
Treace Medical Concepts
TMCI
+$34.9M
2
TGTX icon
TG Therapeutics
TGTX
+$34.1M
3
GSK icon
GSK
GSK
+$33.5M
4
PODD icon
Insulet
PODD
+$28.6M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.8M

Top Sells

Rank Stock Value
1
CRL icon
Charles River Laboratories
CRL
+$23.3M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$13.7M
3
ACLX
Arcellx
ACLX
+$12.3M
4
CVS icon
CVS Health
CVS
+$11.5M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$9.95M

Sector Composition

Rank Sector Weight
1 Healthcare 90.02%
2 Consumer Staples 1.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$91.3M 8.42%
+1,250,000
New +$99.8M
UTHR icon
2
United Therapeutics
UTHR
$26.3B
$64.9M 5.98%
287,165
+44,430
+18% +$10.2M
TEVA icon
3
Teva Pharmaceuticals
TEVA
$35.9B
$61.7M 5.7%
6,052,164
+1,802,164
+42% +$16.8M
FOCL
4
EDAP TMS S.A.
FOCL
$226M
$43.9M 4.05%
6,256,784
+782,562
+14% +$6.22M
SRDX
5
DELISTED
Surmodics
SRDX
$39.5M 3.64%
1,230,862
-105,976
-8% -$3.6M
ORGO icon
6
Organogenesis Holdings
ORGO
$308M
$39.1M 3.61%
12,296,163
+568,100
+5% +$1.81M
GSK icon
7
GSK
GSK
$103B
$34.2M 3.15%
+943,000
New +$33.5M
HUM icon
8
Humana
HUM
$46.7B
$33.5M 3.09%
68,802
+6,052
+10% +$2.84M
IRMD icon
9
iRadimed
IRMD
$1.21B
$27.9M 2.57%
628,206
-145,488
-19% -$6.76M
PCVX icon
10
Vaxcyte
PCVX
$7.89B
$25.5M 2.35%
499,650
-71,600
-13% -$3.53M
TMCI icon
11
Treace Medical Concepts
TMCI
$259M
$25M 2.31%
+1,907,823
New +$34.9M
TGTX icon
12
TG Therapeutics
TGTX
$8.58B
$24.1M 2.22%
2,884,382
+2,448,882
+562% +$34.1M
NPCE icon
13
Neuropace
NPCE
$505M
$24M 2.21%
2,466,205
-9
-0% -$53
ACLX
14
DELISTED
Arcellx
ACLX
$23.1M 2.13%
643,777
-358,222
-36% -$12.3M
TNGX icon
15
Tango Therapeutics
TNGX
$4.34B
$21.7M 2%
1,929,019
+152,122
+9% +$928K
PODD icon
16
Insulet
PODD
$11.3B
$20.4M 1.88%
+127,680
New +$28.6M
EOLS icon
17
Evolus
EOLS
$394M
$19M 1.75%
2,078,000
+1,061,000
+104% +$9.51M
AXGN icon
18
Axogen
AXGN
$2.1B
$18.9M 1.75%
3,785,829
+1,995,831
+111% +$13.8M
CRL icon
19
Charles River Laboratories
CRL
$10.9B
$18.8M 1.74%
96,064
-113,432
-54% -$23.3M
CELC icon
20
Celcuity
CELC
$4.03B
$18.8M 1.73%
2,056,484
+133,201
+7% +$1.31M
SKIN icon
21
SkinHealth Systems
SKIN
$94.9M
$16.9M 1.56%
2,806,720
+324,931
+13% +$2.28M
AXSM icon
22
Axsome Therapeutics
AXSM
$12.4B
$16.6M 1.53%
237,500
+212,600
+854% +$15.9M
SNN icon
23
Smith & Nephew
SNN
$12.9B
$16.2M 1.49%
653,900
+164,632
+34% +$4.62M
RIGL icon
24
Rigel Pharmaceuticals
RIGL
$680M
$16M 1.48%
1,480,302
+62,500
+4% +$752K
IMVT icon
25
Immunovant
IMVT
$8.09B
$15.3M 1.42%
399,599
+226,000
+130% +$5.11M
1
2 3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Soleus Capital Management held 126 positions worth $1.08B, up 20% from $900M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Soleus Capital Management deployed $269M of net new capital in Q3 2023, opening 25 new positions and adding to 29 existing holdings. Its largest new stake was Treace Medical Concepts: 1,907,823 shares worth $25M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 97% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Charles River Laboratories, an estimated $23.3M trimmed.

  • Soleus Capital Management's largest Q3 2023 buy was Treace Medical Concepts: 1,907,823 shares worth $25M.
  • Soleus Capital Management added most to TG Therapeutics in Q3 2023, an estimated $34.1M increase.
  • Soleus Capital Management's biggest Q3 2023 reduction was Charles River Laboratories, cutting an estimated $23.3M.
  • Soleus Capital Management fully exited Seagen Inc. Common Stock in Q3 2023, selling an estimated $13.7M.
  • Soleus Capital Management's ten largest holdings make up 43% of its $1.08B portfolio in Q3 2023.
  • Soleus Capital Management opened 25 new positions and closed 35 in Q3 2023.
  • Soleus Capital Management's portfolio value rose 20% quarter-over-quarter to $1.08B.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.